Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris

NCT01920477 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
35
Enrollment
INDUSTRY
Sponsor class

Stopped Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals